Is it really the case that any company is not trying to update to the Delta spike? how do we know that?
Then, saying that the other companies would not get any competitive advantage for that will depend on the time frames. If one company can release vaccines against new variants quicker than the rest, they would have an advantage there.
You also can’t run studies to prove that your vaccine that’s more resilient to variants actually has that property before those varients arise, so it’s unlikely that market competition would work the way you assume.
That’s a fair point, though you can show at least in theory that a vaccine is effective against all variants that have appeared so far.
Is it really the case that any company is not trying to update to the Delta spike? how do we know that?
Then, saying that the other companies would not get any competitive advantage for that will depend on the time frames. If one company can release vaccines against new variants quicker than the rest, they would have an advantage there.
That’s a fair point, though you can show at least in theory that a vaccine is effective against all variants that have appeared so far.